| Symbol | ADAPY |
|---|---|
| Name | ADAPTIMMUNE THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | OX14 4RY United Kingdom ENG The Innovation Centre, 99 Park Drive Milton Park Abingdon |
| Telephone | (44) 1235 430000 |
| Fax | — |
| — | |
| Website | https://www.adaptimmune.com |
| Incorporation | GB |
| Incorporated On | 2014 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001621227 |
| Description | Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types. Additional info from NASDAQ: |
No news found.
| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06204991 | To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Adva… | Phase1 | Melanoma Stage III | Recruiting | 2025-04-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT04752358 | ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogas… | Phase2 | Esophageal Cancer | Terminated | 2021-09-15 | 2023-12-15 | ClinicalTrials.gov |
| NCT06048705 | Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable)… | Phase1 | Neoplasms | Terminated | 2021-03-09 | 2023-06-08 | ClinicalTrials.gov |
| NCT05943990 | Study of GSK3845097 in Previously Treated Participants With Advanced Synovial S… | Phase1 | Neoplasms | Terminated | 2020-12-21 | 2022-10-24 | ClinicalTrials.gov |
| NCT04526509 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generatio… | Phase1 | Neoplasms | Terminated | 2020-12-21 | 2023-06-08 | ClinicalTrials.gov |
| NCT04408898 | SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer | Phase2 | Head and Neck Cancer | Withdrawn | 2020-07-02 | 2021-12-01 | ClinicalTrials.gov |
| NCT03391791 | Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Recept… | — | Solid and Hematological Malignancies | Terminated | 2018-02-28 | 2018-07-24 | ClinicalTrials.gov |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | Phase1 | Urinary Bladder Cancer | Active_Not_Recruiting | 2017-05-15 | 2032-09-01 | ClinicalTrials.gov |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | Phase1 | Hepatocellular Cancer | Completed | 2017-05-08 | 2025-11-19 | ClinicalTrials.gov |
| NCT02989064 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Phase1 | Urothelial Carcinoma | Completed | 2016-10-01 | 2020-06-04 | ClinicalTrials.gov |
| NCT02636855 | Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for El… | — | Solid and Hematological Malignancies | Completed | 2015-12-01 | 2024-06-28 | ClinicalTrials.gov |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | Phase1 | Non-Small Cell Lung Cancer | Completed | 2015-11-01 | 2021-03-17 | ClinicalTrials.gov |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | Phase1 | Multiple Myeloma | Terminated | 2013-10-15 | 2018-04-09 | ClinicalTrials.gov |
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | Phase1 | Ovarian Cancer | Completed | 2013-07-09 | 2017-06-06 | ClinicalTrials.gov |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced A… | Phase1 | Melanoma | Terminated | 2011-06-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT00991224 | Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy | Phase1 | HIV Infections | Completed | 2009-11-01 | 2014-01-01 | ClinicalTrials.gov |
Total clinical trials: 16
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | Other | Phase PHASE1 | Hepatocellular Cancer | COMPLETED | NCT03132792 |
| Treatment with NY-ESO-1c259-modified T cells | Drug | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01892293 |
| Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT01350401 |
| Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT01350401 |
| NYESO-1c259 T cells | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT01567891 |
| NYESO-1c259 T cells | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT01567891 |
| NYESO-1c259 T cells | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT01567891 |
| STI or Drug Holiday | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT00991224 |
| α/6-gag-TCR modified T cells | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00991224 |
| WT-gag-TCR modified T cells | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00991224 |
| STI or Drug Holiday | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT00991224 |
| α/6-gag-TCR modified T cells | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00991224 |
| WT-gag-TCR modified T cells | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00991224 |
| Genetically engineered T Cell Receptors | Other | Preclinical | Solid and Hematological Malignancies | TERMINATED | NCT03391791 |
| Genetically engineered T Cell Receptors | Other | Preclinical | Solid and Hematological Malignancies | TERMINATED | NCT03391791 |
| Genetically engineered T Cell Receptors | Other | Preclinical | Solid and Hematological Malignancies | TERMINATED | NCT03391791 |
| ADP-A2M4 in combination with pembrolizumab. | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04408898 |
| ADP-A2M4 in combination with pembrolizumab. | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04408898 |
| Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation | Other | Phase PHASE1 | Urinary Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03132922 |
| Autologous genetically modified MAGE-A4ᶜ¹º³²T cells | Other | Phase PHASE1 | Urinary Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03132922 |
| Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation | Other | Phase PHASE1 | Urinary Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03132922 |
| Autologous genetically modified MAGE-A4ᶜ¹º³²T cells | Other | Phase PHASE1 | Urinary Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03132922 |
| ADP adoptive cell therapy | Drug | Phase PHASE1 | Neoplasms | RECRUITING | NCT03391778 |
| Non-conforming afamitresgene autoleucel | Other | Preclinical | Synovial Sarcoma | AVAILABLE | NCT06617572 |
| Fludarabine | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05993299 |
| Cyclophosphamide | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05993299 |
| Letetresgene autoleucel | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05993299 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT06048705 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT06048705 |
| GSK3901961 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT06048705 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT05943990 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT05943990 |
| GSK3845097 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT05943990 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT05943990 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT05943990 |
| GSK3845097 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT05943990 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| GSK4427296 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| GSK3845097 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| GSK3901961 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| GSK4427296 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| GSK3845097 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| GSK3901961 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04526509 |
| Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab | Other | Phase PHASE2 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05601752 |
| Autologous genetically modified ADP-A2M4CD8 cells | Other | Phase PHASE2 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05601752 |
| afamitresgene autoleucel (previously ADP-A2M4) | Other | Phase PHASE2 | Synovial Sarcoma | ACTIVE_NOT_RECRUITING | NCT04044768 |
| Afamitresgene autoleucel | Other | Phase PHASE1 | Synovial Sarcoma | RECRUITING | NCT05642455 |
| Experimental: Letetresgene autoleucel | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT06703346 |
| Cyclophosphamide | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03967223 |
| Fludarabine | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03967223 |
| Letetresgene autoleucel (lete-cel, GSK3377794) | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03967223 |
| Autologous genetically modified AFPᶜ³³²T cells | Other | Phase PHASE1 | Hepatocellular Cancer | ACTIVE_NOT_RECRUITING | NCT03132792 |
| Autologous genetically modified AFPᶜ³³²T cells | Other | Phase PHASE1 | Hepatocellular Cancer | ACTIVE_NOT_RECRUITING | NCT03132792 |
| Proleukin | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| Fludarabine Phosphate | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| Cyclophosphamide | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| ADP-TILIL7 | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| Proleukin | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| Fludarabine Phosphate | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| Cyclophosphamide | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| ADP-TILIL7 | Other | Phase PHASE1 | Melanoma Stage III | RECRUITING | NCT06204991 |
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT02592577 |
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT02592577 |
| Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells | Other | Phase PHASE1 | Urothelial Carcinoma | COMPLETED | NCT02989064 |
Total products: 67